Cetuximab-I21-2 / Shanghai Biophy Biological Pharmaceutical - LARVOL DELTA

Internalization-Dependent EGFR-Targeted Photoactivation by Cetuximab-I21 Conjugates. (PubMed, J Immunother) - "We developed and characterized 2 cetuximab-I21 conjugates, cetuximab-I21-2 and cetuximab-I21-3, targeting epidermal growth factor receptor (EGFR)-expressing tumors. These findings establish cetuximab-I21 as a light-activated, EGFR-targeted antibody-photosensitizer conjugate with a mechanism distinct from that of canonical IR700-based NIR-PIT. Direct IR700 comparison, immune activation studies, photosafety evaluation, and light-dose optimization will be required to define its translational potential."

Journal • Oncology